Updated on 30.03.2026|11:55 AM
Speciality Medicines Limited has announced its Initial Public Offering (IPO) on the BSE SME platform. It is a Mumbai-based marketer and distributor of finished pharmaceutical formulations for complex and chronic conditions.
The subscription will open on March 20, 2026, and close on March 24, 2026, with a price band of ₹117 to ₹124 per share. Track all the IPOs at a place in our upcoming and live IPOs of 2026.
The company operates an integrated B2B model with a portfolio of over 900 products and exports to more than 35 countries across Asia, Africa, Europe, and Latin America.
The 100% fresh issue of 23,50,000 equity shares aims to raise approximately ₹29.14 Crores at the upper price band. Proceeds are earmarked for setting up an in-house R&D centre (₹12.68 Crores), funding international product registrations, and meeting working capital requirements.
In this article, you will find Speciality Medicines IPO GMP today, price band, financial analysis, valuation, strength and risks, industry outl look and a detailed review. For daywise subscription, check our daywise IPO subscription section.
Briefs of Speciality Medicines IPO Details:
- Price Band: ₹117 – ₹124 per equity share
- IPO Open / Close Dates: March 20, 2026 – March 24, 2026
- Lot Size: 1,000 Shares (Note: Retail Minimum Application is 2 Lots / 2,000 Shares)
- Issue Size: 23,50,000 Equity Shares / ~₹29.14 Crores
- Fresh Issue / OFS: 100% Fresh Issue
- Registrar: Skyline Financial Services Pvt. Ltd.
- Listing Exchange: BSE SME
If you as an investor has queries regarding allotment, credit of share, refunds and other similar issues can check our detailed guide on Skyline Financial Services IPO allotment status which has all the important information.
What Is The Speciality Medicines IPO GMP Today?
You can check the GMP of this and other issues at our GMP hub page.
Note: The Grey Market Premium (GMP) changes daily based on market demand. It is an unofficial indicator and is not regularised by SEBI, NSE, or BSE. Investors should not rely solely on GMP for investment decisions.
Listing Updates:
| Type | Issue Price | Open | Gain/loss % |
| Lisiting | 124.00 | 124.00 | 0.00 |
What Are The Important Speciality Medicines IPO Dates & Allotment Schedule?
For investors planning their capital allocation, here is the critical timeline for the issue:
- IPO Open Date: Friday, March 20, 2026
- IPO Close Date: Tuesday, March 24, 2026
- Basis of Allotment Date: Wednesday, March 25, 2026
- Refund Initiation Date: Friday, March 27, 2026
- Credit of Shares: Friday, March 27, 2026
- Listing Date: Monday, March 30, 2026
What Are The Objectives of Speciality Medicines IPO?
The company proposes to utilise the Net Proceeds from the Fresh Issue towards the following strategic purposes:
- Setting up an R&D Centre: A significant ₹12.68 Crores is allocated to establish an in-house R&D centre in Valsad, Gujarat, reducing reliance on third-party contract manufacturers and accelerating product development.
- Working Capital:₹8.00 Crores will be used to meet incremental working capital needs required to support the expanding export operations.
- International Expansion:₹2.99 Crores is earmarked for product registrations and development in target markets across Latin America, Africa, and the Middle East.
- Marketing:₹2.00 Crores to fund marketing and promotional activities globally.
- General Corporate Purposes: The balance will meet ongoing operational exigencies.
How is The Financial Performance of Speciality Medicines?
The following table summarises the financial performance of the company based on restated financial statements.
(Figures in ₹ Crores)
| Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
Total Income | 58.54 | 27.66 | 23.20 |
Profit After Tax (PAT) | 8.61 | 2.93 | 1.70 |
EBITDA | 9.09 | 5.26 | 3.58 |
Total Borrowing | 5.05 | 2.86 | 3.64 |
Assets | 39.98 | 22.68 | 13.26 |
Source: RHP
Financial Analysis & Observations:
Total Income:
The company demonstrated exceptional top-line growth, with Total Income doubling from ₹27.66 Crores in FY24 to ₹58.54 Crores in FY25. This massive 111.71% surge was fueled primarily by robust export sales of unregistered generic products to emerging markets in Latin America and Africa.
Profit After Tax (PAT):
Profitability followed the revenue trajectory, with PAT leaping from ₹2.93 Crores in FY24 to ₹8.61 Crores in FY25. A critical driver of this bottom-line expansion was the company’s DPIIT startup recognition, which granted it a 100% income tax exemption under Section 80-IAC, drastically reducing its tax liability.
EBITDA:
Operational efficiency improved significantly, with EBITDA rising to ₹9.09 Crores in FY25. Although the EBITDA margin dipped slightly from 19.11% in FY24 to 15.60% in FY25, absolute operating profits remain strong due to a favorable product mix of high-demand formulations.
Total Borrowing:
Total borrowings stand at a manageable ₹5.05 Crores as of March 2025. The debt-to-equity ratio remains highly comfortable at 0.17x, indicating that the company’s aggressive expansion is largely funded by internal accruals rather than excessive leverage.
Assets:
The asset base expanded to nearly ₹39.98 Crores by FY25. This growth is heavily concentrated in current assets, particularly inventory and trade receivables, reflecting the working-capital-intensive nature of the global pharma distribution business.
What Are The P/E Ratio and Peer Comparison?
Based on its Fiscal Year 2025 earnings per share (EPS) of ₹14.10, the IPO is priced at a Price-to-Earnings (P/E) multiple of approximately 8.79x at the upper end of the price band (₹124).
P/E Ratio = ₹124(Price) / ₹14.10Earnings Per Share)
P/E Ratio ≈ 8.79x
Peer Comparison Table (FY 2024-25 Data):
| Company | P/E Ratio | RoNW (%) | EPS (₹) |
Speciality Medicines | 8.79 | 28.42 | 14.10 |
| Remus Pharmaceuticals | 12.25 | 15.02 | 65.21 |
| Trident Lifeline | 27.59 | 18.23 | 10.22 |
| Mono Pharmacare | 13.87 | 9.90 | 1.75 |
Analysis:
Speciality Medicines is entering the market at an estimated P/E multiple of approximately 8.79x (based on pre-issue earnings). When compared to the industry average P/E of ~19.92x and listed peers like Trident Lifeline (27.59x) and Remus Pharmaceuticals (12.25x), the issue appears to be priced very attractively.
Furthermore, Speciality Medicines has a Return on Net Worth (RoNW) of 28.42%, significantly outperforming its peers and suggesting highly efficient capital utilisation.
What is The Industry Outlook Speciality Medicines?
Growth Potential:
The global demand for affordable generic and speciality medicines, particularly in emerging markets across Africa, Asia, and Latin America, is growing rapidly. India remains the "pharmacy of the world," providing strong macro tailwinds for export-oriented distributors.
Market Trends:
There is an increasing trend among distributors to backwards integrate by setting up captive R&D capabilities. This allows companies to own product dossiers and intellectual property, capturing higher margins rather than just acting as trading intermediaries.
What Are The Strengths and Risks of Speciality Medicines IPO?
Strengths:
- Geographic Diversification: With nearly 70% of sales coming from exports to over 35 countries, the company is well-hedged against domestic market slowdowns.
- Tax Advantage: The 100% income tax exemption under the startup scheme provides a massive boost to free cash flows, allowing for aggressive reinvestment.
- Strategic R&D Expansion: Utilising IPO funds to build an in-house R&D centre in Gujarat is a clear path to value creation and reduced dependence on third-party manufacturers.
Risks:
- Negative Cash Flows: The company has reported negative cash flows from operating activities for the last three years (₹ -5.79 Crores in FY25) due to high working capital lockup. Sustained negative cash flow is a red flag.
- Pending Criminal Litigation: The Chairman and Managing Director is involved in pending criminal proceedings related to alleged black marketing during the COVID-19 pandemic. An adverse outcome could severely damage reputation and operations.
- Client Concentration: The top 10 customers contribute nearly 75% of total revenue. The loss of a key international client could be detrimental.
Key Considerations for Investors
This section is for information purposes only and does not constitute financial advice.
Investors should note the Minimum Investment structure.
- Minimum Application: The lot size is 1,000 Shares. Based on the data provided, the minimum application for Retail Individual Investors is 2 Lots (2,000 Shares), amounting to ₹2,48,000. Note: This investment amount exceeds the typical ₹2 Lakh retail limit, which implies this category effectively targets Small-HNI investors.
- Valuation: At ~8.8x P/E, the pricing offers a significant discount to industry peers and the broader market.
- Risk Profile: While the growth and tax-free profitability are highly attractive, the negative operating cash flows and the specific legal risks involving the promoter require high risk tolerance from investors.
Key Takeaways
- IPO Price: ₹124 per share (Upper Band).
- Min Investment: ₹2,48,000 (2,000 Shares).
- Financials: Revenue ₹58.5 Cr (FY25);
- Allotment: March 25, 2026.
- Listing: BSE SME platform on March 30, 2026.
FAQs on Speciality Medicines IPO
What is Speciality Medicines IPO GMP today?
The GMP is a dynamic market sentiment indicator. Check the grey market premium at our gmp section.
What is Speciality Medicines IPO price band?
The price band is fixed at ₹117 to ₹124 per equity share.
What is Speciality Medicines IPO allotment date?
The allotment status is expected to be finalized on Wednesday, March 25, 2026.
How to check Speciality Medicines IPO allotment status?
Investors can check the status on the website of Skyline Financial Services Pvt. Ltd. (the Registrar) or via the BSE IPO allotment portal. You can also track our IPO allotment status hub page for details about this and other IPOs at a place.
What is Speciality Medicines IPO listing date?
The shares are tentatively scheduled to list on Monday, March 30, 2026.
Investment Perspective on Speciality Medicines IPO
Speciality Medicines presents a compelling high-growth, high-margin opportunity in the pharma export space, aided by a significant tax advantage. The valuation is priced at a discount to peers. However, the high retail ticket size, negative cash flows, and promoter-level legal risks are critical factors that investors must weigh carefully against the growth potential.
Disclaimer:
This article is strictly for educational purposes. Please consult a SEBI-registered investment advisor before making any investment decisions.
